FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Evguenia Svarovskaia

Research Profile

Living Beings

Physiology

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Michael E Abram; Kristen N Andreatta; Tiffany L Barnes; Xiaowu Chen; Derrick D Goodman; Rebecca M Hluhanich; Nicolas A Margot; Damian McColl; Anita Niedziela-Majka; Nikolai Novikov; Evguenia S Svarovskaia; Kirsten L White; Linda Ye; Michael D Miller
Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness.
Jonathan Z Li; Karin J Metzner; Michael D Miller; Lars Ostergaard; Roger Paredes; Heather J Ribaudo; Evguenia S Svarovskaia; Anna Maria Geretti; Katherine Huppler Hullsiek; Martin R Jakobsen; Jeffrey A Johnson; Michael J Kozal; Daniel R Kuritzkes
Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure.
Evguenia S Svarovskaia; Y Zhu; F Zoulim; F Lavocat; M D Miller; T Berg; Katyna Borroto-Esoda; M Curtis; K M Kitrinos
Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Evguenia Svarovskaia (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Michael E Abram; Kristen N Andreatta; Tiffany L Barnes; Xiaowu Chen; Derrick D Goodman; Rebecca M Hluhanich; Nicolas A Margot; Damian McColl; Anita Niedziela-Majka; Nikolai Novikov; Evguenia S Svarovskaia; Kirsten L White; Linda Ye; Michael D Miller
Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness.
Antimicrobial agents and chemotherapy 2013;57(6):2654-63.
2013: Jonathan Z Li; Karin J Metzner; Michael D Miller; Lars Ostergaard; Roger Paredes; Heather J Ribaudo; Evguenia S Svarovskaia; Anna Maria Geretti; Katherine Huppler Hullsiek; Martin R Jakobsen; Jeffrey A Johnson; Michael J Kozal; Daniel R Kuritzkes
Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure.
The Journal of infectious diseases 2013;207(6):893-7.
2013: Evguenia S Svarovskaia; Y Zhu; F Zoulim; F Lavocat; M D Miller; T Berg; Katyna Borroto-Esoda; M Curtis; K M Kitrinos
Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen.
Journal of viral hepatitis 2013;20(2):131-40.
2013: Severine Margeridon-Thermet; Ross Martin; Mary Pacold; Elizabeth C Reuman; Farbod Babrzadeh; Katyna Borroto-Esoda; Susan P Holmes; Tommy F Liu; Evguenia S Svarovskaia; Robert W Shafer
Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment.
Antimicrobial agents and chemotherapy 2013;57(1):343-9.
2012: Evguenia S Svarovskaia; Ross Martin; John G McHutchison; Michael D Miller; Hongmei Mo
Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy.
Journal of clinical microbiology 2012;50(10):3267-74.
2012: Jonathan Z Li; Michael D Miller; Roger Paredes; Heather J Ribaudo; Evguenia S Svarovskaia; David R Bangsberg; Katherine Huppler Hullsiek; Michael J Kozal; Daniel R Kuritzkes
Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure.
AIDS (London, England) 2012;26(2):185-92.
2011: Andrew S Bae; Karin S Ku; M Miller; Hongmei Mo; Evguenia S Svarovskaia
Allele-specific real-time PCR system for detection of subpopulations of genotype 1a and 1b hepatitis C NS5B Y448H mutant viruses in clinical samples.
Journal of clinical microbiology 2011;49(9):3168-74.
2011: Jonathan Z Li; Roger Paredes; Heather J Ribaudo; Evguenia S Svarovskaia; Karin J Metzner; Michael J Kozal; Kathy Huppler Hullsiek; Melanie Balduin; Martin R Jakobsen; Anna Maria Geretti; Rodolphe Thiebaut; Lars Ostergaard; Bernard Masquelier; Jeffrey A Johnson; Michael D Miller; Daniel R Kuritzkes
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis.
JAMA : the journal of the American Medical Association 2011;305(13):1327-35.
2011: Andrea Snow-Lampart; Brandi Chappell; Maria Curtis; Yuao Zhu; Florence Myrick; James Schawalder; Kathryn Kitrinos; Evguenia S Svarovskaia; Michael D Miller; Jeff Sorbel; Jenny Heathcote; Patrick Marcellin; Katyna Borroto-Esoda
No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus.
Hepatology (Baltimore, Md.) 2011;53(3):763-73.
2011: Derrick D Goodman; Yun Zhou; Nicolas A Margot; Damian J McColl; Lijie Zhong; Katyna Borroto-Esoda; Michael D Miller; Evguenia S Svarovskaia
Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy.
AIDS (London, England) 2011;25(3):325-33.
2010: Elizabeth C Reuman; Severine Margeridon-Thermet; Harrison B Caudill; Tommy Liu; Katyna Borroto-Esoda; Evguenia S Svarovskaia; Susan P Holmes; Robert W Shafer
A classification model for G-to-A hypermutation in hepatitis B virus ultra-deep pyrosequencing reads.
Bioinformatics (Oxford, England) 2010;26(23):2929-32.
2009: Joy Y Feng; John K Ly; Florence Myrick; Derrick Goodman; Kirsten L White; Evguenia S Svarovskaia; Katyna Borroto-Esoda; Michael D Miller
The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study.
Retrovirology 2009;6():44.
2009: Joshua M Waters; Wesley O'Neal; Kirsten L White; Charles Wakeford; Eric B Lansdon; Jeanette Harris; Evguenia S Svarovskaia; Michael D Miller; Katyna Borroto-Esoda
Mutations in the thumb-connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients.
Antiviral therapy 2009;14(2):231-9.
2008: Evguenia S Svarovskaia; Joy Y Feng; Nicolas A Margot; Florence Myrick; Derrick Goodman; John K Ly; Kirsten L White; Nilima Kutty; Ruth Wang; Katyna Borroto-Esoda; M Miller
The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation.
Journal of acquired immune deficiency syndromes (1999) 2008;48(4):428-36.
2007: Evguenia S Svarovskaia; Nicolas A Margot; Andrew S Bae; Joshua M Waters; Derrick Goodman; Lijie Zhong; Katyna Borroto-Esoda; M Miller
Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine.
Journal of acquired immune deficiency syndromes (1999) 2007;46(2):174-80.
2007: Jean L Mbisa; Rebekah Barr; James A Thomas; Nick Vandegraaff; Irene J Dorweiler; Evguenia S Svarovskaia; William L Brown; Louis M Mansky; Robert J Gorelick; Reuben S Harris; Alan Engelman; Vinay K Pathak
Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration.
Journal of virology 2007;81(13):7099-110.
2006: Evguenia S Svarovskaia; Michael J Moser; Andrew S Bae; James R Prudent; M Miller; Katyna Borroto-Esoda
MultiCode-RTx real-time PCR system for detection of subpopulations of K65R human immunodeficiency virus type 1 reverse transcriptase mutant viruses in clinical samples.
Journal of clinical microbiology 2006;44(11):4237-41.
2004: Evguenia S Svarovskaia; Hongzhan Xu; Jean L Mbisa; Rebekah Barr; Robert J Gorelick; Akira Ono; Eric O Freed; Wei-Shau Hu; Vinay K Pathak
Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.
The Journal of biological chemistry 2004;279(34):35822-8.
2004: Galina N Nikolenko; Evguenia S Svarovskaia; Krista A Delviks; Vinay K Pathak
Antiretroviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase increase template-switching frequency.
Journal of virology 2004;78(16):8761-70.
2004: Hongzhan Xu; Evguenia S Svarovskaia; Rebekah Barr; Yijun Zhang; Mohammad Khan; Klaus Strebel; Vinay K Pathak
A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(15):5652-7.
2004: Evguenia S Svarovskaia; Rebekah Barr; Xuechun Zhang; Godwin C G Pais; Christophe Marchand; Yves Pommier; Terrence R Burke; Vinay K Pathak
Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions.
Journal of virology 2004;78(7):3210-22.
2003: Xuechun Zhang; Godwin C G Pais; Evguenia S Svarovskaia; Christophe Marchand; Allison A Johnson; Rajeshri G Karki; Marc C Nicklaus; Vinay K Pathak; Yves Pommier; Terrence R Burke
Azido-containing aryl beta-diketo acid HIV-1 integrase inhibitors.
Bioorganic & medicinal chemistry letters 2003;13(6):1215-9.
2003: Evguenia S Svarovskaia; Sara Rasmussen Cheslock; Wen-Hui Zhang; Wei-Shau Hu; Vinay K Pathak
Retroviral mutation rates and reverse transcriptase fidelity.
Frontiers in bioscience : a journal and virtual library 2003;8():d117-34.
2002: Wen-Hui Zhang; Evguenia S Svarovskaia; Rebekah Barr; Vinay K Pathak
Y586F mutation in murine leukemia virus reverse transcriptase decreases fidelity of DNA synthesis in regions associated with adenine-thymine tracts.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(15):10090-5.
2002: Godwin C G Pais; Xuechun Zhang; Christophe Marchand; Nouri Neamati; Kiriana Cowansage; Evguenia S Svarovskaia; Vinay K Pathak; Yun Tang; Marc C Nicklaus; Yves Pommier; Terrence R Burke
Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors.
Journal of medicinal chemistry 2002;45(15):3184-94.
2001: Carey K Hwang; Evguenia S Svarovskaia; Vinay K Pathak
Dynamic copy choice: steady state between murine leukemia virus polymerase and polymerase-dependent RNase H activity determines frequency of in vivo template switching.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(21):12209-14.
2000: EK Halvas; Evguenia S Svarovskaia; Vinay K Pathak
Role of murine leukemia virus reverse transcriptase deoxyribonucleoside triphosphate-binding site in retroviral replication and in vivo fidelity.
Journal of virology 2000;74(22):10349-58.
2000: Evguenia S Svarovskaia; Krista A Delviks; Carey K Hwang; Vinay K Pathak
Structural determinants of murine leukemia virus reverse transcriptase that affect the frequency of template switching.
Journal of virology 2000;74(15):7171-8.
2000: EK Halvas; Evguenia S Svarovskaia; Eric O Freed; Vinay K Pathak
Wild-type and YMDD mutant murine leukemia virus reverse transcriptases are resistant to 2',3'-dideoxy-3'-thiacytidine.
Journal of virology 2000;74(14):6669-74.
2000: EK Halvas; Evguenia S Svarovskaia; Vinay K Pathak
Development of an in vivo assay to identify structural determinants in murine leukemia virus reverse transcriptase important for fidelity.
Journal of virology 2000;74(1):312-9.
1997: Galina N Nikolenko; V V Kravchenko; Evguenia S Svarovskaia; Irina Gileva; V A Likhoshvaĭ; V G Korobko
[Regulation of translation of the distal lacZ gene in polycistronic mRNA by the ribosome stream from the proximal gene].
Bioorganicheskaia khimiia 1997;23(3):200-4.